FGF21 and metabolic dysfunction-associated steatohepatitis: Although previous clinical trials with pegozafermin and other FGF21 analogs have consistently demonstrated improvements in lipids in both healthy volunteers and patients with NASH or diabetes, FGF21 analogs have not been assessed in SHTG23,25–29.